** Biotech company Voyager Therapeutics' shares rise 6.9% to $6.18 premarket
** Wedbush analyst Yun Zhong starts coverage on stock with "outperform" rating and PT at $11; previous Wedbush analyst covering stock had a "neutral" rating and PT of $7
** The new PT is a 90.3% upside to the stock's last close
** Brokerage says positive data from VYGR's programs targeting neurodegenerative disorders, including Alzheimer's and ALS, have boosted their confidence
** Wedbush says shares are trading low, creating an "attractive investment opportunity" despite the high risks of early-stage treatments
** All ten brokerages rate the stock "buy" or higher; their median PT is $18 - LSEG
** As of last close, stock has fallen 31.5% YTD
(Reporting by Kamal Choudhury)
((Kamal.Choudhury@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。